Type of information: Milestone
Company: Abbvie (USA - IL) Argen-X (Belgium)
Therapeutic area: Cancer - Oncology
Type agreement: development, commercialisation
Action mechanism: monoclonal antibody. ARGX-115 is a preclinical-stage human antibody program targeting the novel immuno-oncology target GARP, a protein believed to contribute to immuno-suppressive effects of T-cells. Tumors grow and progress as they escape from immune surveillance, owing to their ability to suppress the immune system by co-opting different immunosuppressive cells such as regulatory T-cells (Tregs), which can inhibit other immune effector cells through the production of active TGF-Beta. The membrane protein GARP play a key role in the regulation of production of active TGF-Beta by Tregs. Preclinical studies completed at de Duve Institute/UCL/WELBIO show ARGX-115 can inhibit the immunosuppressive activity of human Tregs by binding to GARP-inactive TGF-Beta complex and preventing release of active TGF-Beta. ARGX-115 was discovered under argenx' Innovative Access Program with the de Duve Institute / Université Catholique de Louvain /WELBIO.
Financial terms: argenx will receive an upfront payment of $40 million from AbbVie for the exclusive option to license ARGX-115 and near-term preclinical milestones of $20 million. argenx is also eligible to receive additional development, regulatory and commercial payments up to $625 million upon achievement of pre-determined milestones as well as tiered, up to double-digit royalties on net sales upon commercialization.
Latest news: • On April 13, 2017, argenx announced the achievement of the first of two preclinical milestones on its way to the investigational new drug filing of ARGX-115, triggering a first $ 10 million payment from AbbVie.